The FDA database recorded a supplement dated 2 September 2026 to biologics licence application BLA761420 for Avtozma (tocilizumab-anoh), Celltrion's biosimilar to tocilizumab.
The record does not state what the supplement concerns. Biosimilar supplements commonly cover manufacturing changes, new presentations or labelling updates to match the reference product, and are not in themselves safety actions. Nothing in the record indicates a new indication, interchangeability designation, safety communication or recall.
Tocilizumab biosimilars matter for access to IL-6 inhibition in rheumatoid arthritis and giant cell arteritis. No change in prescribing follows from this entry.
- No change to prescribing is indicated by this record
- Check FDA labelling directly if a biosimilar's presentation or indication matters for a patient
- Continue standard monitoring on tocilizumab — neutrophils, liver enzymes, lipids, infection risk
Why it matters
Biosimilar regulatory activity shapes access to IL-6 inhibition, but this entry changes nothing for prescribers today.
Don't overread it
A licence supplement is administrative — it is not a new indication or safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free